Home › Research › Brain scans and imaging
Evaluation of Tau Radiotracers in Chronic Traumatic Encephalopathy
Varlow C, Vasdev N.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022-09-15
Topic: Brain proteins, microglia and lab models
Plain-language summary
3 H-flortaucipir demonstrated a positive signal in all CTE cases examined, with varying degrees of specific binding (68.7% ± 10.5%; n = 12) defined by homologous blockade and to a lesser extent by heterologous blockade with MK-6240 (27.3% ± 13.6%; n = 12). The 3 H-flortaucipir signal was also displaced by the monoamine oxidase (MAO)-A inhibitor clorgyline (43.9% ± 4.6%; n = 3), indicating off-target binding to MAO-A. 3 H-APN-1607 was moderately displaced in homologous blocking studies and was not displaced by 3 H-flortaucipir; however, substantial displacement was observed when blocking with the β-amyloid-targeting compound NAV-4694. 3 H-MK-6240 and 3 H-PI-2620 had negligible binding in all but 2 CTE IV cases, and binding may be attributed to pathology severity or mixed Alzheimer disease/CTE pathology. 3 H-CBD-2115 showed moderate binding, displaced under homologous blockade, and aligned with 4R-tau immunostaining. In human CTE tissues, 3 H-flortaucipir and 3 H-APN-1607 revealed off-target binding to MAO-A and amyloid-β, respectively, and should be considered if these radiotracers are used in PET imaging studies of patients with brain injuries. 3 H-MK-6240 and 3 H-PI-2620 bind to CTE tau in severe- or mixed-pathology cases, and their respective 18 F PET radiotracers warrant further evaluation in patients with severe suspected CTE.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Varlow, C., & Vasdev, N. (2023). Evaluation of Tau Radiotracers in Chronic Traumatic Encephalopathy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. https://doi.org/10.2967/jnumed.122.264404
Vancouver
Varlow C, Vasdev N. Evaluation of Tau Radiotracers in Chronic Traumatic Encephalopathy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2023. doi:10.2967/jnumed.122.264404. PMID: 36109185.
BibTeX
@article{varlow2023-36109185,
author = {Varlow, C. and Vasdev, N.},
title = {{Evaluation of Tau Radiotracers in Chronic Traumatic Encephalopathy}},
journal = {Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
year = {2023},
doi = {10.2967/jnumed.122.264404},
pmid = {36109185},
url = {https://doi.org/10.2967/jnumed.122.264404}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- 3 H-flortaucipir demonstrated a positive signal in all CTE cases examined, with varying degrees of specific binding (68.7% ± 10.5%; n = 12) defined by homologous blockade and to a lesser extent by heterologous blockade with MK-6240 (27.3% ± 13.6%; n = 12).
- The 3 H-flortaucipir signal was also displaced by the monoamine oxidase (MAO)-A inhibitor clorgyline (43.9% ± 4.6%; n = 3), indicating off-target binding to MAO-A. 3 H-APN-1607 was moderately displaced in homologous blocking studies and was not displaced by 3 H-flortaucipir; however, substantial displacement was observed when blocking with the β-amyloid-targeting compound NAV-4694. 3 H-MK-6240 and 3 H-PI-2620 had negligible binding in all but 2 CTE IV cases, and binding may be attributed to pathology severity or mixed Alzheimer disease/CTE pathology. 3 H-CBD-2115 showed moderate binding, displaced under homologous blockade, and aligned with 4R-tau immunostaining.
- In human CTE tissues, 3 H-flortaucipir and 3 H-APN-1607 revealed off-target binding to MAO-A and amyloid-β, respectively, and should be considered if these radiotracers are used in PET imaging studies of patients with brain injuries. 3 H-MK-6240 and 3 H-PI-2620 bind to CTE tau in severe- or mixed-pathology cases, and their respective 18 F PET radiotracers warrant further evaluation in patients with severe suspected CTE.
New to this subject? Start with our plain-English guide: Brain scans & tests →
Study details
- Participants12
- Effect size68.7%; 10.5%; 27.3%
- Evidence strengthLow
How this study scored 50/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 29 of the 58 points we could judge it on, which is 50 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of nuclear medicine : official publication, Society of Nuclear Medicine) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 12 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 36109185) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 29 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 29 of the 58 points we could judge it on is 50 out of 100. |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.